Verseon
Fremont, US · Founded 2002 · Delaware corporation · 22 employees on LinkedIn
Find your way into Verseon
15 people in our graph share verified history with the Verseon team — schools, employers, funds. One of them is your warm intro.
Vish Mishraunlockedknows Adityo Prakash · together at Verseon (overlapped)
×11knows the team · via Babes-Bolyai University
Verseon uses quantum physics-based modeling combined with AI to design novel small-molecule drug candidates for major human diseases. Its pipeline targets conditions including cardiovascular disease (anticoagulants), diabetic vision loss, multidrug-resistant cancers, and solid-tumor metastasis, with candidates ranging from preclinical to clinical stages.
Founders & leadership
Verseon was founded in 2002 by Adityo Prakash, David Kita, and Eniko Fodor.
AP
Adityo PrakashinCo-founder · CEOAdityo Prakash is the founder and CEO of Verseon, which develops small-molecule drug candidates using quantum physics-based computational modeling and AI. He previously founded and led Pulsent Corporation, a company focused on foundational video streaming technologies.
DK
David KitainVP of R&D / Cofounder • Drug Discovery • Translational Research • Clinical DevelopmentDavid Kita is cofounder and an executive officer at Verseon, where he leads drug discovery and translational research programs. He holds a Ph.D. in theoretical astrophysics from the University of Wisconsin–Madison and brings over 20 years of experience in small-molecule drug discovery, computational chemistry, clinical trials, and R&D management across cardiovascular, oncology, and ophthalmology indications.
EF
Eniko FodorinCo-founder · COOEniko Fodor cofounded and leads Verseon, which develops AI-driven small-molecule drug candidates for diseases including cardiovascular conditions and cancers. He previously served as COO at Pulsent, where he contributed to the company's core technology development.
Reported raises · per SEC filings
Form D private placements$25M disclosed across 7 rounds · 2005–2019
▶$101.4KraisedApr 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$101.4KraisedApr 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HechtDirector
- Sangtae KimDirector
- Eniko FodorExecutive Officer, Director
- Adityo PrakashExecutive Officer, Director
- David KitaExecutive Officer
- Offering amount
- $101.4K
- Amount sold
- $101.4K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$451KraisedMay 2015 · 10 investors · PharmaceuticalsRule 506(b)
▶$451KraisedMay 2015 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adityo PrakashExecutive Officer, Director
- Eniko FodorExecutive Officer, Director
- David KitaExecutive Officer
- Offering amount
- $451K
- Amount sold
- $451K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.8MraisedMay 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$11.8MraisedMay 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eniko FodorExecutive Officer, Director
- Adityo PrakashExecutive Officer, Director
- David KitaExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- First sale
- Sep 2009
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.5MraisedMay 2015 · 22 investors · PharmaceuticalsRule 506(b)
▶$6.5MraisedMay 2015 · 22 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KitaExecutive Officer
- Adityo PrakashExecutive Officer, Director
- Eniko FodorExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Oct 2005
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$69.8KraisedMay 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$69.8KraisedMay 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KitaExecutive Officer
- Eniko FodorExecutive Officer, Director
- Adityo PrakashExecutive Officer, Director
- Offering amount
- $69.8K
- Amount sold
- $69.8K
- First sale
- Jun 2011
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$259.6KraisedMay 2015 · 13 investors · PharmaceuticalsRule 506(b)
▶$259.6KraisedMay 2015 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KitaExecutive Officer
- Adityo PrakashExecutive Officer, Director
- Eniko FodorExecutive Officer, Director
- Offering amount
- $259.6K
- Amount sold
- $259.6K
- First sale
- Sep 2010
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedMay 2015 · 28 investors · PharmaceuticalsRule 506(b)
▶$5.8MraisedMay 2015 · 28 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Adityo PrakashExecutive Officer, Director
- David KitaExecutive Officer
- Eniko FodorExecutive Officer, Director
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- Feb 2008
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapRegeneron NASDAQ: REGN www.regeneron.com11 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Geron7 shared keywordsGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.
Starton Therapeutics7 shared keywordsStarton Therapeutics is a clinical-stage biotechnology company that reformulates FDA-approved drugs using proprietary controlled delivery systems to improve their pharmacokinetic profiles. It develops subcutaneous, oral, and transdermal delivery methods aimed at achieving better outcomes in existing or new indications.
Lexicon Pharmaceuticals7 shared keywords
Companies competing with Verseon for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Verseon do?
- Verseon uses quantum physics-based modeling combined with AI to design novel small-molecule drug candidates for major human diseases. Its pipeline targets conditions including cardiovascular disease (anticoagulants), diabetic vision loss, multidrug-resistant cancers, and solid-tumor metastasis, with candidates ranging from preclinical to clinical stages.
- Who founded Verseon?
- Verseon was founded by Adityo Prakash, David Kita, Eniko Fodor in 2002.
- How much funding has Verseon raised?
- Verseon has disclosed $25M raised across 7 rounds.
- Where is Verseon headquartered?
- Verseon is headquartered in Fremont, US.